CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 3
Montreal, Quebec, Canada and 81 other locations
the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...
Phase 3
Montréal, Quebec, Canada and 154 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Montréal, Quebec, Canada and 71 other locations
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
Montreal, Quebec, Canada and 58 other locations
The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the com...
Phase 3
Montreal, Quebec, Canada and 107 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Montreal, Quebec, Canada and 67 other locations
use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma...
Phase 2
Montreal, Quebec, Canada and 103 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Montréal, Quebec, Canada and 32 other locations
and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...
Phase 3
Montreal, Quebec, Canada and 130 other locations
study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma...
Phase 2, Phase 3
Montreal, Quebec, Canada and 126 other locations
Clinical trials
Research sites
Resources
Legal